VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
BDXBecton, Dickinson and Company
$155.54$56.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

BDX logoBecton, Dickinson and Company(BDX)Earnings, Financials & Key Ratios

BDX•NYSE
$155.54
26.7× P/E·Price updated Jul 6, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryDrug delivery and infusion consumables
AboutBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.Show more
  • Revenue$21.84B+8.2%
  • EBITDA$5.04B+7.6%
  • Net Income$1.68B-1.6%
  • EPS (Diluted)5.83-0.5%
  • Gross Margin45.44%+0.5%
  • EBITDA Margin23.08%-0.6%
  • Operating Margin11.8%-0.6%
  • Net Margin7.68%-9.1%
  • ROE6.54%-0.8%

BDX Price & Volume

Becton, Dickinson and Company (BDX) stock price & volume — 10-year historical chart

Loading chart...

Operational Contraction Challenges Becton Dickinson Financial Stability

Investment Thesis • Updated 2026Q2

VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Vulnerable
Cash Flow:Deteriorating
Primary Risk:Regulatory and compliance remediation

Key Thesis Takeaways

  • Becton, Dickinson and Company faces a critical inflection point as revenue growth contracted by 10.6% in 2026Q2, signaling significant volatility in its core medical disposables business.
  • The company's reliance on $26.0 billion in goodwill, representing over 50% of total assets, combined with a deteriorating current ratio of 0.94, suggests heightened balance sheet vulnerability.
  • Investors should monitor whether management can stabilize operating margins, which plummeted to 2.0% in the most recent quarter, before committing capital to this turnaround effort.

Verdict Logic

the company's inability to maintain a current ratio above 1.0 and the sharp 10.6% revenue contraction in 2026Q2 suggest significant operational and liquidity risks that outweigh the current 2.7% dividend yield.

BDX Growth Metrics

Becton, Dickinson and Company (BDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years7.82%
5 Years6.32%
3 Years4.99%
TTM2.39%

Profit CAGR

10 Years9.21%
5 Years13.93%
3 Years-1.93%
TTM-24.03%

EPS CAGR

10 Years5.7%
5 Years16.56%
3 Years-0.28%
TTM-24.62%

Return on Capital

10 Years4.62%
5 Years4.95%
3 Years5.04%
Last Year5.41%

BDX Recent Earnings

Becton, Dickinson and Company (BDX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$2.90+4.3%
$2.78
Rev
$4.7B+0.9%
$4.7B
Q1 2026
Feb 9, 2026
Metric
Actual
Est
EPS
$2.91+31.7%
$2.21
Rev
$4.5B-12.8%
$5.1B
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$3.96+1.0%
$3.92
Rev
$5.9B-0.3%
$5.9B
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$3.68+8.2%
$3.40
Rev
$5.5B+0.4%
$5.5B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$2.90vs $2.78+4.3%
$4.7Bvs $4.7B+0.9%
Q1 2026Feb 9, 2026
$2.91vs $2.21+31.7%
$4.5Bvs $5.1B-12.8%
Q4 2025Nov 6, 2025
$3.96vs $3.92+1.0%
$5.9Bvs $5.9B-0.3%
Q3 2025Aug 7, 2025
$3.68vs $3.40+8.2%
$5.5Bvs $5.5B+0.4%
Based on last 12 quarters of dataView full earnings history →

Latest BDX News

Recent stock market news and headlines for Becton, Dickinson and Company (BDX)

PRNewsWire·Jun 23, 2026
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.

Fool - Investing News·Jun 22, 2026
5 Dividend Stocks to Buy and Hold Forever

Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.

The Motley Fool·Jun 22, 2026
3 Excellent Dividend Stocks to Buy on the Dip

Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.

Finbold·Jun 19, 2026
Rep Thomas Kean just filed 4 new congressional stock trades

Representative Thomas H. Kean Jr, a Republican from New Jersey who sits on the House Energy and Commerce Committee, has disclosed four new congressional stock trades.

Forbes·Jun 17, 2026
The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Peers Comparison

Key metrics vs top competitors for Becton, Dickinson and Company (BDX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
BDX logoBDXBecton, Dickinson and CompanyCurrent
$155.54$56.35B26.688.23%7.68%6.54%2.68%
BAX logoBAXBaxter International Inc.
$22.58$11.66B-12.905.72%-9.7%-16.5%—
BSX logoBSXBoston Scientific Corporation
$44.60$66.29B22.9919.87%17.23%14.67%—
MDT logoMDTMedtronic plc
$83.06$106.64B22.278.43%13.2%9.78%—
SYK logoSYKStryker Corporation
$313.38$120.14B37.3111.16%13.21%15.1%—
ZBH logoZBHZimmer Biomet Holdings, Inc.
$89.76$17.58B25.287.2%9.05%5.77%—

Compare BDX vs Peers

Becton, Dickinson and Company (BDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BAX

Most directly comparable listed peer for BDX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BDX against a more recognizable public peer.

Peer Set

Compare Top 5

vs BAX, BSX, MDT, SYK

BDX SEC Filings & Documents

Becton, Dickinson and Company (BDX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 12, 2026·SEC

Material company update

May 7, 2026·SEC

Material company update

Apr 29, 2026·SEC

10-K Annual Reports

2
FY 2025

Nov 25, 2025·SEC

FY 2024

Nov 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2026

Feb 9, 2026·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when BDX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

BDX Frequently Asked Questions

Becton, Dickinson and Company (BDX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Becton, Dickinson and Company's revenue?

Becton, Dickinson and Company (BDX) reported $21.36B in revenue for fiscal year 2025. This represents a 671% increase from $2.77B in 1996.

How fast is Becton, Dickinson and Company growing?

Becton, Dickinson and Company (BDX) grew revenue by 8.2% over the past year. This is steady growth.

Is BDX profitable?

Yes, Becton, Dickinson and Company (BDX) is profitable, generating $1.14B in net income for fiscal year 2025 (7.7% net margin).

Dividend & Returns
Does BDX pay dividends?

Yes, Becton, Dickinson and Company (BDX) pays a dividend with a yield of 2.68%. This makes it attractive for income-focused investors.

What is BDX's return on equity?

Becton, Dickinson and Company (BDX) has a return on equity (ROE) of 6.5%. This is below average, suggesting room for improvement.

What is Becton, Dickinson and Company's free cash flow?

Becton, Dickinson and Company (BDX) generated $3.14B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in BDX back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →